Cutaneous Reaction to BNT162b2 Mrna COVID-19 Vaccine.

International Journal of DermatologyVolume 60, Issue 7 p. 891-892 Correspondence Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine Correction(s) for this article Corrigendum Volume 62Issue 8International Journal of Dermatology pages: 1101-1101 First Published online: March 8, 2022 Alba López-Valle MD, Corresponding Author Alba López-Valle MD [email protected] orcid.org/0000-0001-6650-8614 Department of Dermatology, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this authorDaniel Falkenhain-López MD, Daniel Falkenhain-López MD Department of Dermatology, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this authorCelia Ruiz-Arranz MD, Celia Ruiz-Arranz MD Ophthalmology Department, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this author Alba López-Valle MD, Corresponding Author Alba López-Valle MD [email protected] orcid.org/0000-0001-6650-8614 Department of Dermatology, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this authorDaniel Falkenhain-López MD, Daniel Falkenhain-López MD Department of Dermatology, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this authorCelia Ruiz-Arranz MD, Celia Ruiz-Arranz MD Ophthalmology Department, Hospital 12 de Octubre, Madrid, SpainSearch for more papers by this author First published: 14 April 2021 https://doi.org/10.1111/ijd.15575Citations: 6 Conflict of interest: None. Funding source: None. [Correction added on March 5, 2022 after first online publication: the last author name has been corrected as Celia Ruiz-Arranz.] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261–279. 10.1038/nrd.2017.243 CASPubMedWeb of Science®Google Scholar 2Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615. 10.1056/NEJMoa2034577 CASPubMedWeb of Science®Google Scholar 3Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416. 10.1056/NEJMoa2035389 CASPubMedWeb of Science®Google Scholar 4Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther 2017; 25: 1316–1327. 10.1016/j.ymthe.2017.03.035 CASPubMedWeb of Science®Google Scholar 5Stone CA, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol 2019; 85: 2694–2706. 10.1111/bcp.14112 PubMedWeb of Science®Google Scholar Citing Literature Volume60, Issue7July 2021Pages 891-892 ReferencesRelatedInformation